Connection
Jonathan Kaufman to Vincristine
This is a "connection" page, showing publications Jonathan Kaufman has written about Vincristine.
|
|
Connection Strength |
|
 |
|
 |
|
0.078 |
|
|
|
-
Cohen JB, Switchenko JM, Koff JL, Sinha R, Kaufman JL, Khoury HJ, Bumpers N, Colbert A, Hutchison-Rzepka A, Nastoupil LJ, Heffner LT, Langston AA, Lechowicz MJ, Lonial S, Flowers CR. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. Br J Haematol. 2015 Nov; 171(4):539-46.
Score: 0.031
-
Sinha R, Kaufman JL, Khoury HJ, King N, Shenoy PJ, Lewis C, Bumpers K, Hutchison-Rzepka A, Tighiouart M, Heffner LT, Lechowicz MJ, Lonial S, Flowers CR. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. Cancer. 2012 Jul 15; 118(14):3538-48.
Score: 0.024
-
Muringampurath-John D, Flowers CR, Toscano M, Zhengjia C, Kaufman JL, Arellano M, Bernal-Mizrachi L, Heffner LT, Lechowicz MJ, McLemore M, Winton E, Jaye DL, Lonial S, Khoury HJ. Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2012 Apr; 53(4):725-7.
Score: 0.024
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|